The global live cell imaging market in terms of revenue was estimated to be worth $1.8 billion in 2020 and is poised to reach $2.8 billion by 2025, growing at a CAGR of 8.8% from 2020 to 2025.

Growing adoption of high-content screening techniques in drug discovery and rising incidence of cancer primarily drives the market for live cell imaging. The growth in research funding and rising government funding and investment in regenerative medicine research will also support the market growth in the coming years. However, the high cost of high-content screening systems is limiting the overall adoption of these products.

The traditional method of toxicity and drug safety studies involves the screening of large libraries through high-throughput screening. This method is expensive, has a low success rate, and is resource- and time-consuming.

To overcome these challenges, pharmaceutical companies are increasingly adopting high-content screening (HCS) cell-based assays for identifying the effects of toxicity in drug development studies (cell-based imaging enables the monitoring of drug toxicity mechanisms, such as oxidative stress, micronuclei, mitochondrial dysfunction, steatosis, and apoptosis).

The use of HCS makes the drug development process more time- and cost-efficient. Owing to these factors, the adoption of high-content screening for toxicity studies is expected to increase during the forecast period.

According to the new market research report "Live Cell Imaging Market by Product (Instruments, Consumables, Software, Services) Application (Cell Biology, Drug Discovery) Technology (Time-lapse Microscopy, FRET) End User (Contract Research Organization, Research Institutes) - Global Forecast to 2025", published by MarketsandMarkets™, the global market size is projected to reach USD 2.8 billion by 2025 from USD 1.8 billion in 2020, at a CAGR of 8.8% during the forecast period.

Browse in-depth TOC on "Live Cell Imaging Market"

146 – Tables
40 – Figures
212 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163914483

The growing adoption of high-content screening techniques in drug discovery, rising incidence of cancer, and the growth in funding for research are the major factors driving the growth of this market.

"The reagents segment is expected for the largest share of the live cell imaging market in 2019."

Based on type, the live cell imaging consumables market is segmented into reagents, media, assay kits, and other consumables (microplates, slides, Petri dishes, coverslips, and culture chambers). In 2019, the reagents segment accounted for the largest share of 36.1% of the consumables market.